60 Degrees Pharmaceuticals (SXTP) Other Non Operating Income (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Other Non Operating Income of $10762.0 for Q1 2026, down 64.51% year-over-year from $30322.0 in Q1 2025, and down 31.59% quarter-over-quarter from $15732.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Other Non Operating Income (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Other Non Operating Income for 5 consecutive years, with $10762.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 64.51% year-over-year to $10762.0; the TTM figure through Mar 2026 stood at $71110.0 (down 83.71% YoY), while the FY2025 annual figure was $90670.0, down 79.27% from the prior year.
- Other Non Operating Income slipped to $10762.0 in Q1 2026 per SXTP's latest filing, from $15732.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $369938.0 in Q4 2024 and bottomed at -$839887.0 in Q1 2023.
- Historically, Other Non Operating Income has averaged -$5644.1 across 5 years, with a median of $18153.5 in 2024.
- Annual changes were most pronounced in 2023 — Other Non Operating Income jumped 511.16% — and 2025, when it slumped 95.75%.
- 60 Degrees Pharmaceuticals' Other Non Operating Income stood at $144179.0 in 2022, then plunged by 35.85% to $92490.0 in 2023, then surged by 299.98% to $369938.0 in 2024, then plunged by 95.75% to $15732.0 in 2025, then plunged by 31.59% to $10762.0 in 2026.
- Business Quant data shows SXTP's Other Non Operating Income at $10762.0 in Q1 2026, $15732.0 in Q4 2025, and $31550.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10,762.00 |
| Dec 31, 2025 | 15,732.00 |
| Sep 30, 2025 | 31,550.00 |
| Jun 30, 2025 | 13,066.00 |
| Mar 31, 2025 | 30,322.00 |
| Dec 31, 2024 | 369,938.00 |
| Sep 30, 2024 | 16,623.00 |
| Jun 30, 2024 | 19,684.00 |
| Mar 31, 2024 | 31,051.00 |
| Sep 30, 2023 | 92,490.00 |
| Jun 30, 2023 | 7,968.00 |
| Mar 31, 2023 | -839,887.00 |
| Dec 31, 2022 | 144,179.00 |
| Sep 30, 2022 | -22,495.00 |